Cornerstone Pharmaceuticals to Present at 9th Annual Biotech Showcase™ in San Francisco, January 9-11, 2017

CRANBURY, N.J., Dec. 22, 2016  /PRNewswire/ --

WHAT: Cornerstone Pharmaceuticals will present to investors and biopharmaceutical executives from around the world. The 9^th Annual Conference Biotech Showcase™ is one of the largest annual healthcare conferences around the world and will take place in San Francisco concurrently to the J.P. Morgan 35^th Annual Healthcare Conference. Members of Cornerstone's management team will present information on its Altered Energy Metabolism Directed (AEMD) platform, update on clinical trials for its lead compound CPI-613, and future strategy.

Interviews prior and during the conference available upon request:

• Presenters:
  • Sanjeev Luther, Chief Operating Officer, Cornerstone Pharmaceuticals
  • Timothy S. Pardee, MD, PhD, Chief Oncologist, Cornerstone Pharmaceuticals
• Board Members:
  • Howard Jonas, Chairman of the Board, Cornerstone Pharmaceuticals
  • Jean-Pierre Sommadossi, PhD, Principal Founder, Chairman and CEO of Atea Pharmaceuticals, Vice Chairman of Cornerstone Pharmaceuticals Board of Directors

WHERE: 9^th Annual Conference Biotech Showcase, Hilton San Francisco Union Square, San Francisco, California

WHEN: January 11, 2016, 2:30 – 3:00pm PT

CONTACT: Kara Golub, 609-456-0822 or kgolub@jfkhealth.com, for more information.                

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's investors include IDT Corporation (NYSE: IDT). Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS). www.cornerstonepharma.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-to-present-at-9th-annual-biotech-showcase-in-san-francisco-january-9-11-2017-300382876.html

SOURCE Cornerstone Pharmaceuticals, Inc.